Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S de Bono

Showing results (291-300 of 426) with videos related to

Pageof 43
Sort By:
The Lancet. Oncology|August 13, 2021
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trialJohann S de Bono, Niven Mehra, Giorgio V Scagliotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studiesTimothy A Yap, David Olmos, Andre T Brunetto, et al.
The Lancet. Oncology|September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Howard I Scher, Arturo Molina, et al.
Cancer Research|May 20, 2016
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer CellsRoberta Ferraldeschi, Jonathan Welti, Marissa V Powers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2015
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone AcetateGerhardt Attard, Johann S de Bono, Christopher J Logothetis, et al.
Clinical Pharmacology and Therapeutics|August 21, 2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor TuvusertibJatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, et al.
Cancer Reports (Hoboken, N.J.)|February 22, 2023
Systematic study of tissue factor expression in solid tumorsJohann S de Bono, Jeffrey R Harris, Saskia M Burm, et al.
Investigational New Drugs|November 1, 2019
Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)Ruud van der Noll, Agnes Jager, Joo Ern Ang, et al.
Molecular Cancer Therapeutics|June 23, 2017
Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic MelanomaJoo Ern Ang, Akos Pal, Yasmin J Asad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical QualificationGeorge Seed, Wei Yuan, Joaquin Mateo, et al.
Pageof 43

Showing results (291-300 of 426) with videos related to

Sort By:
Pageof 43
The Lancet. Oncology|August 13, 2021
Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trialJohann S de Bono, Niven Mehra, Giorgio V Scagliotti, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 9, 2011
Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studiesTimothy A Yap, David Olmos, Andre T Brunetto, et al.
The Lancet. Oncology|September 22, 2012
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 studyKarim Fizazi, Howard I Scher, Arturo Molina, et al.
Cancer Research|May 20, 2016
Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer CellsRoberta Ferraldeschi, Jonathan Welti, Marissa V Powers, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 17, 2015
Improvements in Radiographic Progression-Free Survival Stratified by ERG Gene Status in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Abiraterone AcetateGerhardt Attard, Johann S de Bono, Christopher J Logothetis, et al.
Clinical Pharmacology and Therapeutics|August 21, 2025
Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor TuvusertibJatinder Kaur Mukker, Paul Matthias Diderichsen, Farina Hellmann, et al.
Cancer Reports (Hoboken, N.J.)|February 22, 2023
Systematic study of tissue factor expression in solid tumorsJohann S de Bono, Jeffrey R Harris, Saskia M Burm, et al.
Investigational New Drugs|November 1, 2019
Phase I study of continuous olaparib capsule dosing in combination with carboplatin and/or paclitaxel (Part 1)Ruud van der Noll, Agnes Jager, Joo Ern Ang, et al.
Molecular Cancer Therapeutics|June 23, 2017
Modulation of Plasma Metabolite Biomarkers of the MAPK Pathway with MEK Inhibitor RO4987655: Pharmacodynamic and Predictive Potential in Metastatic MelanomaJoo Ern Ang, Akos Pal, Yasmin J Asad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2017
Gene Copy Number Estimation from Targeted Next-Generation Sequencing of Prostate Cancer Biopsies: Analytic Validation and Clinical QualificationGeorge Seed, Wei Yuan, Joaquin Mateo, et al.
Pageof 43